ArcticZymes Technologies — Earnings Release 2016

Oct 26, 2016

Biotec Pharmacon: Q3 2016 Results

Biotec Pharmacon: Q3 2016 Results

(Tromsø, 25 October 2016) Biotec Pharmacon ASA ("Biotec", OSE: BIOTEC) reported

sales of NOK 21.1 million (16.4) in the third quarter of 2016, and a negative

EBITDA of NOK 5.9 million (-3.5). Biotec continues to deliver on 2016 goals

through ArcticZymes product expansion and confirmation of reimbursement by one

of the largest insurance companies for two regions in Germany

- We are very pleased with the progress we have seen in the last quarter. Good

sales growth in both the beta-glucan and enzyme units together with solid

progress in some of the focus areas for Woulgan® is encouraging. We also see the

Woulgan® brand is becoming more and more recognized in the markets we operate

in, says Svein Lien, Chief Executive Officer of Biotec.

Sales in the third quarter 2016 ended at NOK 21.1 million (16.4) with an EBITDA

of NOK -5.9 million (-3.5). Sales from beta-glucans and enzymes were NOK 15.1

and 6.0 million, respectively. The company has a good financial position with a

cash balance of NOK 64.7 million at the end of the second quarter.

Biotec responded to additional questions from the UK Drug Tariff during the

third quarter. While waiting for reimbursement in the UK, Biotec and its UK

distributor H&R Healthcare continue to promote Woulgan® with additional case

studies and KOL support. Woulgan® is also gaining positive momentum in the

Nordic market by combined efforts with its distributor Navamedic. Several Nordic

tenders are submitted and under review. Biotec obtained the first tender in

Sweden during the third quarter

-We reached several important milestones in the German market during the third

quarter. Confirmation of reimbursement by one of the leading insurance companies

and the recently announced first supply agreement with a homecare company puts

us in a good position for further commercial expansion in this important market,

say Lien

Biotec reiterates its 2016 operational targets for Woulgan®, presented at the

company's Capital Markets Day on 11 February 2016.

The complete interim report for Q3 2016 is enclosed. The company is hosting a

presentation on 26 October 2016 at 08:30 CET at Hotel Continental, Stortingsgata

24, Oslo.

For additional information,

Svein Lien, CEO, +47 922 89 323, svein.lien@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, an advanced wound care product

for stalled wounds with a proprietary medicinal ingredient. ArcticZymes

develops, produces and markets recombinant enzymes of marine origin used in

molecular DNA technologies and diagnostics, representing growth markets where

rapid technological developments are creating a strong demand for new and

improved enzymes.